Idrocilamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Idrocilamide
Idrocilamide.png
Clinical data
Trade names Talval, Srilane, Relaxnova, Brolitène
AHFS/Drugs.com International Drug Names
Routes of
administration
Topical
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.027.414
Chemical and physical data
Formula C11H13NO2
Molar mass 191.226 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Idrocilamide (trade names Talval, Srilane, Relaxnova, Brolitène[1]) is a medication with skeletal muscle relaxant[2] and anti-inflammatory actions[3] used as a topical cream to treat lumbago and other kinds of muscular pain;[4] it is available on prescription or over-the-counter[citation needed] in France and various other countries.[1]

Interactions[edit]

Idrocilamide has been reported to be a potent inhibitor of the metabolism of caffeine.[5][6]

References[edit]

  1. ^ a b Drugs.com: International Drug Names
  2. ^ Bouron A, Rivet M, Nasri-Sebdani M, Guillemain J, Durbin P, Guerrier D, Raymond G (1990). "The direct depressant effect of LCB29 (idrocilamide) on mechanical tension of rat soleus muscle fibers". Canadian Journal of Physiology and Pharmacology. 68 (12): 1503–1509. PMID 2085796. doi:10.1139/y90-228. 
  3. ^ Bannwarth B, Le Huec JC, Vinçon G, Labat L, Demotes-Mainard F, Rivaille F, Le Rebeller A (1993). "[Tissue and systemic diffusion of idrocilamide after cutaneous administration]". Revue du Rhumatisme (in French). 60 (12): 932–6. PMID 8012322. 
  4. ^ Stehman M, Lehert P (1990). "Clinical double-blind study with idrocilamide ointment in the treatment of acute lumbago". Acta Belgica. Medica Physica. 13 (1): 29–32. PMID 2140002. 
  5. ^ Carrillo JA, Benitez J (2000). "Clinically significant pharmacokinetic interactions between dietary caffeine and medications". Clinical Pharmacokinetics. 39 (2): 127–53. PMID 10976659. doi:10.2165/00003088-200039020-00004. 
  6. ^ Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux JC (1980). "Inhibition by idrocilamide of the disposition of caffeine". European Journal of Clinical Pharmacology. 17 (1): 37–43. PMID 7371698. doi:10.1007/bf00561675.